Article History

Received: 21 November 2019

Accepted: 24 February 2020

First Online: 14 March 2020

Change Date: 23 June 2020

Change Type: Correction

Change Details: The original version of this article unfortunately contained an error. In the Conflict of interest statement, Anne-Marie Quinson is described as declaring no conflict of interest.

Change Date: 31 May 2020

Change Type: Correction

Change Details: The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Compliance with ethical standards

:

: Frank Kroschinsky reports receiving reimbursement for costs of study treatments, documentation, congress fees and travel expenses from Boehringer Ingelheim. Jan Moritz Middeke declares that he has no conflict of interest. Martin Janz declares that he has no conflict of interest. Georg Lenz reports personal fees and/or research support from Amgen, AstraZeneca, BMS, Abbvie, Bayer, Janssen, Novartis, Gilead / Kite, Celgene, Roche, Takeda, Morphosys, ACERTA, AQUINOX, Agios, Verastem, NanoString, and Springer, outside the submitted work. Mathias Witzens-Harig declares that he has no conflict of interest. Reda Bouabdallah declares that he has no conflict of interest. Paul La Rosée reports personal fees from Boehringer Ingelheim (Travel support). Andreas Viardot reports personal fees and non-financial support from Roche, personal fees and non-financial support from Kite/Gilead, non-financial support from Abbvie, personal fees from Amgen, outside the submitted work. Gilles Salles reports personal fees from Amgen, BMS, Abbvie, Janssen, Merck, Novartis, Gilead / Kite, Epizyme, Pfizer, Celgene, Roche, Takeda, Autolus, MOrphosys, ACERTA, and Servier, outside the submitted work. Seok Jin Kim declares that he has no conflict of interest. Tae Min Kim declares that he has no conflict of interest. Oliver Ottmann declares that he has no conflict of interest. Joerg Chromik declares that he has no conflict of interest. Anne-Marie Quinson declares that he has no conflict of interest. Ute von Wangenheim and Ute Burkard are employees of Boehringer Ingelheim. Andreas Berk is an employee of ClinTriCare GmbH & Co. KG, contracted by Boehringer Ingelheim. Norbert Schmitz declares that he has no conflict of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.